News
MDBIF
--
NaN%
--
TrivarX Limited Announces Resignation of Director John Mathias
TipRanks · 2d ago
TrivarX Limited Announces Director’s Interest Change
TipRanks · 4d ago
TrivarX Limited Director Acquires New Options
TipRanks · 4d ago
TrivarX Limited Announces Director’s Interest Changes
TipRanks · 4d ago
TrivarX Limited Issues Shares to Settle Director Fees
TipRanks · 4d ago
TrivarX Limited Faces First Strike on Remuneration Report at AGM
TipRanks · 11/21 02:28
TrivarX Limited Updates Securities Issuance Details
TipRanks · 11/12 00:57
TrivarX Limited Updates Securities Issue Announcement
TipRanks · 11/12 00:57
TrivarX Limited Schedules General Meeting to Vote on Key Share Issuances
TipRanks · 11/12 00:47
TrivarX Limited Advances Acquisition of Innovative Brain Imaging Technology
TipRanks · 11/04 22:57
TrivarX Advances Mental Health Diagnostics and Expands into Neuro-Oncology
TipRanks · 10/30 23:40
TrivarX Limited Issues 5 Million Unlisted Options
TipRanks · 10/29 02:08
TrivarX Limited Announces Quotation of New Securities on ASX
TipRanks · 10/27 00:38
TrivarX Limited Announces New Securities Issuance
TipRanks · 10/27 00:28
TrivarX Limited Announces Proposed Securities Issue
TipRanks · 10/22 03:38
TrivarX Limited Announces 2025 Annual General Meeting Details
TipRanks · 10/22 03:09
TrivarX Completes Patient Recruitment in Veteran Mental Health Trial
TipRanks · 10/21 22:40
TrivarX Limited Announces Significant Securities Issue
TipRanks · 10/16 00:10
TrivarX Limited Announces Proposed Securities Issuance
TipRanks · 10/16 00:10
TrivarX Limited Acquires Stabl-Im Technology for Enhanced Brain Tumor Detection
TipRanks · 10/16 00:10
More
Webull provides a variety of real-time MDBIF stock news. You can receive the latest news about TrivarX through multiple platforms. This information may help you make smarter investment decisions.
About MDBIF
TrivarX Limited, formerly Medibio Limited, is an Australia-based mental health technology company engaged in the use of objective measures to aid in the early detection and screening of mental health conditions. Through the Company’s corporate health product, it offers mental well-being solutions for businesses and is also developing products to serve the healthcare provider market. The principal activity of the Company is development of artificial intelligence (AI)-driven, scientifically based devices for screening and diagnosis of behavioral health conditions. Its clinical research has enabled the development of proprietary algorithms for spectral analyses of sleep architecture and heart-rate variability. The Company’s lead product, MEB-001 analyses the data from a standard sleep study to identify depression at a sensitivity of over 85%. Its technology analyses the electrical signals from the brain and the heart to identify mental illness.